Drugs / Emapunil
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07697183 | May 2026 → Jun 2027 expected | pulmonary arterial hypertension | Imperial College London | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT02181582 | Jun 2014 → Jun 2016 | — | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07682233 | Mar 2026 → Sep 2028 expected | — | Imperial College London | Recruiting | No outcome recorded |
| Phase 2 | NCT07191821 | Aug 2025 → Mar 2027 expected | Alzheimer disease | Imperial College London | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT00108836 | Mar 2005 → May 2006 | generalized anxiety disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT06035861 | Aug → Oct 2026 expected | pulmonary arterial hypertension | Imperial College London | Not yet recruiting | No outcome recorded |
| — | NCT07362290 | Sep 2025 → Feb 2026 overdue | — | Imperial College London | Enrolling by invitation | No outcome recorded |
| — | NCT06643013 | Oct 2024 → Apr 2028 expected | cerebrovascular disorder | Imperial College London | Recruiting | No outcome recorded |
| — | NCT03850301 | Jan 2018 → Jan 2025 overdue | multiple sclerosis | Imperial College London | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT02086240 Background | Mar 2014 → Jan 2018 | neurodegenerative disease | Imperial College London | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emapunil | “XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity.” NCT02086240 ↗2“XBD173 (Emapunil) is a phenylpurine that has recently been investigated for the treatment of anxiety, but is not licensed.” NCT03850301 ↗ |
| Known as | AC-5216 | ChEMBL registry synonym — accepted as the source's own label CHEMBL513922 ↗ |
| Known as | Emapunilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL513922 ↗ |
| Known as | XBD173 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07682233 ↗ |
| Action | Activate | “acts as a selective agonist at the peripheral benzodiazepine receptor” NCT02086240 ↗ |
| Modality | Small molecule | “XBD173 (Emapunil) is a phenylpurine” NCT03850301 ↗ |
| Route | Oral | “the subject will be given an oral dose of XBD173 (up to 90mg).” NCT02086240 ↗ |
| Target | TSPO | “binds to TSPO” NCT06643013 ↗ |